Myelofibrosis epidemiology and demographics

Jump to navigation Jump to search

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis epidemiology and demographics

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis epidemiology and demographics

CDC on Myelofibrosis epidemiology and demographics

Myelofibrosis epidemiology and demographics in the news

Blogs on Myelofibrosis epidemiology and demographics

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide. Myelofibrosis is a disease that tends to affect the middle-aged and elderly population with a mean age of 60 years at diagnosis. Males are more commonly affected than females. The male to female ratio is approximately 1.5 to 1. Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.

Epidemiology and Demographics

Prevalence

  • The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.[1]
  • In developed countries, the prevalence of myelofibrosis is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.[2]

Incidence

  • In the countries of the European Union, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average incidence of 1.1 per 100,000 persons.[2]
  • In Olmstead County, Minnesota USA, the annual incidence of primary myelofibrosis has been reported to be 1.33 per 100,000.[3]

Age

Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[1][4][5]

Gender

  • Gender distribution can differ by the subtype of the disease with primary myelofibrosis being more prevalent in males and post-essential thrombocythemia being more common in females.[6]
  • Males are more commonly affected with myelofibrosis than females with a male to female ratio of approximately 1.5 to 1.[7]

Race

  • Myelofibrosis is more prevalent in the Ashkenazi Jews with an evidence of genetic transmission.[8]

References

  1. 1.0 1.1 Epidemiology of myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 8, 2016
  2. 2.0 2.1 Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (April 2014). "Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union". Eur. J. Haematol. 92 (4): 289–97. doi:10.1111/ejh.12256. PMID 24372927.
  3. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  4. Cloran F, Banks KP (March 2007). "AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly". AJR Am J Roentgenol. 188 (3 Suppl): S18–20. doi:10.2214/AJR.05.2141. PMID 17312082.
  5. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E (November 1997). "[Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients]". Med Clin (Barc) (in Spanish; Castilian). 109 (17): 651–5. PMID 9488952.
  6. Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA (January 2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.
  7. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R; et al. (2012). "One thousand patients with primary myelofibrosis: the mayo clinic experience". Mayo Clin Proc. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. PMC 3538387. PMID 22212965.
  8. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.


Template:WikiDoc Sources